CRITICS试验符合方案分析:胃癌D2术后辅助化疗优于放化疗
CRITICS随机试验纳入788例可切除胃癌或食管胃结合部腺癌患者,随机接受术后化疗或放化疗。符合方案分析纳入478例实际开始分配术后治疗的患者,中位随访6.7年,化疗组5年总生存率57.9%,放化疗组45.5%,调整后风险比1.62(P=0.0004),化疗组显著更优。
要点
- D2术后开始辅助治疗的患者中,化疗组5年总生存率显著高于放化疗组。
- 调整后CRT相对CT的HR为1.62(95%CI 1.24-2.12),P=0.0004。
- 逆概率加权分析得到相似风险比,支持结果稳健。
核心结论
- 在CRITICS试验的符合方案分析中,调整已知混杂因素后,术后化疗组5年总生存率显著优于术后放化疗组。
研究设计与样本
- CRITICS为随机对照试验,纳入788例Ib-Iva期可切除胃癌或食管胃结合部腺癌患者,随机分配术后化疗或放化疗。
- 本分析仅纳入实际开始分配术后治疗的患者,共478例,化疗组233例(59%),放化疗组245例(62%)。
- 采用调整比例风险回归和逆概率加权分析以减小选择偏倚。
主要发现
- 中位随访6.7年,化疗组5年总生存率57.9%(95%CI 51.4%-64.3%),放化疗组45.5%(95%CI 39.2%-51.8%)。
- 调整后放化疗相对化疗的风险比为1.62(95%CI 1.24-2.12),P=0.0004。
- 逆概率加权分析得到相似的风险比。
临床怎么用
- 对于D2术后开始辅助治疗的可切除胃癌患者,术后化疗可能优于术后放化疗。
局限性
- 符合方案分析仅纳入实际开始分配术后治疗的患者,可能引入选择偏倚,尽管采用了调整和加权分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Intergroup 0116 and the MAGIC trials changed clinical practice for resectable gastric cancer in the Western world. In these trials, overall survival improved with post-operative chemoradiotherapy (CRT) and perioperative chemotherapy (CT). Intention-to-treat analysis in the CRITICS trial of post-operative CT or post-operative CRT did not show a survival difference. The current study reports on the per-protocol (PP) analysis of the CRITICS trial. PATIENTS AND METHODS: The CRITICS trial was a randomized, controlled trial in which 788 patients with stage Ib-Iva resectable gastric or esophagogastric adenocarcinoma were included. Before start of preoperative CT, patients from the Netherlands, Sweden and Denmark were randomly assigned to receive post-operative CT or CRT. For the current analysis, only patients who started their allocated post-operative treatment were included. Since it is uncertain that the two treatment arms are balanced in such PP analysis, adjusted proportional hazards regression analysis and inverse probability weighted analysis were used to minimize the risk of selection bias and to estimate and compare overall and event-free survival. RESULTS: Of the 788 patients, 478 started post-operative treatment according to protocol, 233 (59%) patients in the CT group and 245 (62%) patients in the CRT group. Patient and tumor characteristics between the groups before start of the post-operative treatment were not different. After a median follow-up of 6.7 years since the start of post-operative treatment, the 5-year overall survival was 57.9% (95% confidence interval: 51.4% to 64.3%) in the CT group versus 45.5% (95% confidence interval: 39.2% to 51.8%) in the CRT group (adjusted hazard ratio CRT versus CT: 1.62 (1.24-2.12), P = 0.0004). Inverse probability weighted analysis resulted in similar hazard ratios. CONCLUSION: After adjustment for all known confounding factors, the PP analysis of patients who started the allocated post-operative treatment in the CRITICS trial showed that the CT group had a significantly better 5-year overall survival than the CRT group (NCT00407186).
引用
- de Steur WO, van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol. 2020. PMID: 33227408. doi:10.1016/j.annonc.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。